Statistics from Altmetric.com
Osteoarthritis (OA) is the most common joint disorder and the major cause of chronic musculoskeletal pain and mobility disability in elderly populations worldwide.1 Currently there is no effective pharmacological treatment for OA, necessitating joint replacement to reduce joint pain and improve physical functions at advanced stages of the disease.2 It has been reported that abnormal subchondral bone resorption and bone loss play an important role in both OA initiation and progression.3–5 Therefore, antiresorptive drugs are suggested to be potential OA therapies.6 We read with deep interest a recent article published in this journal by Neogi et al, who found that in elderly women with newly diagnosed knee OA, those who use bisphosphonates had lower risk of knee replacement than non-users, and suggested that treatment with bisphosphonates has a potential beneficial effect on knee OA.7 We really appreciate the great work performed by the authors; nevertheless, some worthwhile issues need to be further explored.
First, the definition of knee OA at baseline is not clearly described in the study. Nowadays there is no consensus on the classification criteria of knee OA despite extensive epidemiological and clinical studies. The two criteria most frequently used are the American College of Rheumatology (ACR) classification criteria8 and the Kellgren and Lawrence (K-L) system.9 The ACR classification criteria depend on clinical (such as pain, aching or …
Contributors All authors were involved in the study conception and manuscript design, manuscript drafting and revising, and final approval of the submitted version.
Funding The work was supported by the National Natural Science Foundation of China (NSFC #81601930) and Natural Science Foundation of Guangxi (2017GXNSFAA198318 and 2016GXNSFBA380007).
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.